Skip to main content
. Author manuscript; available in PMC: 2019 Aug 28.
Published in final edited form as: J Control Release. 2018 Jun 5;284:171–178. doi: 10.1016/j.jconrel.2018.06.002

Figure 2. A mouse model of pre-existing anti-PEG immunity confirmed PBPK model predictions.

Figure 2

PBPK model predictions (solid and dashed lines) of APA’s impact on PLD PK in mice, plotted against encapsulated in vivo data from mice given PLD +/− APA, with APA starting concentration of 7μg/mL (A) or 300ng/mL (B). (C) The estimated fraction of PLD particles from mPBPK model with a specific number of APA attached over the first fifteen minutes following injection, modeled for high pre-existing APA. (D) The estimated proportion of PLD particles from mPBPK model with a specific number of APA attached through 96 hours post-injection, modeled with a low pre-existing APA. E) mPBPK model’s prediction of doxorubicin AUC with and without APA, compared to in vivo measurements. (F) Measured concentrations of encapsulated and released doxorubicin in the plasma of mice with or without APA at the 5 minute and 3-hour timepoints.